• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    7/31/25 4:10:41 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MNMD alert in real time by email
    8-K
    false000181381400018138142025-07-312025-07-31

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): July 31, 2025

     

     

    Mind Medicine (MindMed) Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    British Columbia

    001-40360

    98-1582438

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    One World Trade Center

    Suite 8500

     

    New York, New York

     

    10007

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (212) 220-6633

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Shares

     

    MNMD

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On July 31, 2025, Mind Medicine (MindMed) Inc. (the “Company”) issued a press release announcing its financial results for its second quarter ended June 30, 2025, as well as information regarding a conference call to discuss these financial results and the Company’s recent corporate highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.

    The information contained in this Item 2.02 of this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

    Item 8.01 Other Events.

    On July 31, 2025, the Company posted an updated corporate presentation on its website. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference in this Item 8.01.

    Item 9.01 Financial Statements and Exhibits.

    Exhibit No.

    Description

    99.1

    Press Release, dated July 31, 2025

    99.2

     

    Corporate Presentation, posted July 31, 2025

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    MIND MEDICINE (MINDMED) INC.

     

     

     

     

    Date:

    July 31, 2025

    By:

    /s/ Robert Barrow

     

     

     

    Name: Robert Barrow
    Title: Chief Executive Officer

     


    Get the next $MNMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MNMD

    DatePrice TargetRatingAnalyst
    8/4/2025$25.00Outperform
    Oppenheimer
    1/28/2025$23.00Outperform
    Evercore ISI
    12/20/2024$20.00Buy
    Chardan Capital Markets
    10/14/2024$20.00Outperform
    Leerink Partners
    7/24/2024$36.00Buy
    ROTH MKM
    5/29/2024$27.00Outperform
    Robert W. Baird
    4/15/2024$20.00Outperform
    Leerink Partners
    12/5/2023$9.00Buy
    Canaccord Genuity
    More analyst ratings

    $MNMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on MindMed with a new price target

    Oppenheimer resumed coverage of MindMed with a rating of Outperform and set a new price target of $25.00

    8/4/25 8:21:56 AM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Evercore ISI initiated coverage on MindMed with a new price target

    Evercore ISI initiated coverage of MindMed with a rating of Outperform and set a new price target of $23.00

    1/28/25 7:14:33 AM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Chardan Capital Markets initiated coverage on MindMed with a new price target

    Chardan Capital Markets initiated coverage of MindMed with a rating of Buy and set a new price target of $20.00

    12/20/24 7:44:37 AM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MNMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gryska David W bought $17,925 worth of shares (2,500 units at $7.17), increasing direct ownership by 14% to 19,851 units (SEC Form 4)

    4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

    12/5/24 4:30:05 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Gryska David W bought $20,930 worth of shares (3,500 units at $5.98), increasing direct ownership by 25% to 17,351 units (SEC Form 4)

    4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

    8/26/24 7:00:03 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Barrow Robert bought $6,215 worth of shares (1,000 units at $6.21), increasing direct ownership by 0.18% to 565,543 units (SEC Form 4)

    4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

    8/20/24 9:14:04 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MNMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Sullivan Mark sold $78,139 worth of shares (11,491 units at $6.80), decreasing direct ownership by 4% to 305,130 units (SEC Form 4)

    4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

    6/26/25 4:30:09 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Barrow Robert sold $180,139 worth of shares (26,491 units at $6.80), decreasing direct ownership by 3% to 830,065 units (SEC Form 4)

    4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

    6/26/25 4:30:04 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Medical Officer Karlin Daniel sold $53,366 worth of shares (7,848 units at $6.80), decreasing direct ownership by 2% to 438,329 units (SEC Form 4)

    4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

    6/26/25 4:30:05 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MNMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $MNMD
    SEC Filings

    View All

    MindMed Announces New Employee Inducement Grants

    Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of (i) options to purchase an aggregate of 425,450 common shares of the Company (the "Options") and (ii) 34,500 performance share units (the "PSUs") (assuming achievement at target levels of performance) that, if earned, will be settled in MindMed common shares upon vesting, with effective grant dates of July 25, 2025, August 4, 2025 and August 11, 2025, depending on the applicable employee's respecti

    8/11/25 4:01:00 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    MindMed Reports Q2 2025 Financial Results and Business Updates

    --Strong enrollment continues in all three Phase 3 trials of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD)-- --Data from the Phase 3 Voyage trial in GAD anticipated in 1H 2026 and data from the Phase 3 Panorama trial in GAD and Phase 3 Emerge trial in MDD anticipated in 2H 2026-- --Strengthened leadership team with appointment of Brandi L. Roberts as Chief Financial Officer-- --Conference call scheduled today at 4:30 p.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders,

    7/31/25 4:01:00 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

    Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, July 31, 2025 to report financial results for the first quarter ended June 30, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the web

    7/24/25 7:00:00 AM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Mind Medicine (MindMed) Inc.

    10-Q - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

    7/31/25 4:20:53 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

    7/31/25 4:10:41 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 144 filed by Mind Medicine (MindMed) Inc.

    144 - Mind Medicine (MindMed) Inc. (0001813814) (Subject)

    6/25/25 4:07:28 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MNMD
    Leadership Updates

    Live Leadership Updates

    View All

    MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

    Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Brandi L. Roberts as its Chief Financial Officer (CFO), effective June 2, 2025. In her new role, Ms. Roberts will join MindMed's executive leadership team where she will oversee all aspects of financial strategy, capital planning, accounting, investor relations and information technology as the Company advances its clinical development and commercial priorities for its lead product candidate MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD

    5/27/25 7:00:00 AM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    MindMed Appoints Matt Wiley as Chief Commercial Officer

    Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley as its Chief Commercial Officer (CCO). In his new role, Mr. Wiley will serve as a member of the executive team, overseeing the Company's commercial vision and strategy as it prepares for the potential launch of its first product, MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317

    3/17/25 7:00:00 AM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

    Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive innovation and growth of MindMed's R&D operations as the Company prepares to initiate three Phase 3 studies of MM120 orally disintegrating tablet (ODT) in generalized anxiety disorder and major depressive disorder. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203094211/en/Javier Muniz,

    12/3/24 7:00:00 AM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MNMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mind Medicine (MindMed) Inc.

    SC 13G/A - Mind Medicine (MindMed) Inc. (0001813814) (Subject)

    11/14/24 4:05:16 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Mind Medicine (MindMed) Inc.

    SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)

    3/21/24 4:05:38 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Mind Medicine (MindMed) Inc.

    SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)

    3/15/24 4:08:37 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MNMD
    Financials

    Live finance-specific insights

    View All

    MindMed Reports Q2 2025 Financial Results and Business Updates

    --Strong enrollment continues in all three Phase 3 trials of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD)-- --Data from the Phase 3 Voyage trial in GAD anticipated in 1H 2026 and data from the Phase 3 Panorama trial in GAD and Phase 3 Emerge trial in MDD anticipated in 2H 2026-- --Strengthened leadership team with appointment of Brandi L. Roberts as Chief Financial Officer-- --Conference call scheduled today at 4:30 p.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders,

    7/31/25 4:01:00 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

    Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, July 31, 2025 to report financial results for the first quarter ended June 30, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the web

    7/24/25 7:00:00 AM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

    --Dosed first patient in Emerge, the first Phase 3 study of MM120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD); 12-week topline data anticipated in 2H 2026-- --Enrollment on track in Phase 3 Voyage and Panorama studies of MM120 (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama-- --Company to host a conference call today at 8:00 a.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its first quarter 2025 financial results and pro

    5/8/25 7:00:00 AM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care